Close Menu

NEW YORK (GenomeWeb) – Goldman Sachs on Wednesday downgraded shares of Qiagen and Bruker to a Sell rating.

The investment bank also lowered its six-month price target for Qiagen to $19 from a prior target of $21 and the 12-month price target for Bruker to $15 from $21.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.

NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.

In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.

In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.